St.-Antonius-Hospital gGmbH

The trials here

What the 16 trials at this site are about, from their registry records.

Conditions

• Multiple myeloma5 trials
• Metastatic breast cancer3 trials
• Triple-negative breast cancer3 trials
• Acute lymphoblastic leukaemia1 trial
• Acute myeloid leukaemia1 trial
• Follicular lymphoma1 trial
• Hodgkin lymphoma1 trial
• Lung cancer1 trial
• Mantle cell lymphoma1 trial

Phase

• Phase 310 trials
• Phase 25 trials
• Phase 41 trial

Status

• Recruiting7 trials
• Active, not recruiting5 trials
• Completed4 trials

Lead sponsor

• University Of Cologne2 trials
• University of Heidelberg Medical Center2 trials
• Women's Cancer Study Group GmbH2 trials
• Genmab1 trial
• Goethe University1 trial
• and 8 more

Running trials

• Not yet recruiting

  NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer

  NCT07178730· Phase 3· Women's Cancer Study Group GmbH· Source

• Recruiting

  Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management

  NCT07371585· Phase 2· SOLTI Breast Cancer Research Group· Source

• Recruiting

  Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer

  NCT06954480· Phase 2· Queen Mary University of London· Source

• Recruiting

  A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

  NCT06623422· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)

  NCT06081244· Phase 3· Women's Cancer Study Group GmbH· Source

• Recruiting

  A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma (GMMG-HD9/DSMM XVIII-trial)

  2023-507402-13-00· Phase 3· Universitaetsklinikum Heidelberg AöR· Source

• Active, not recruiting

  Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

  NCT06191744· Phase 3· Genmab· Source

• Recruiting

  Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT

  NCT06061094· Phase 2· Goethe University· Source

• Active, not recruiting

  Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy - DECIDER-2 trial

  2023-507461-26-00· Phase 3· Medical Center - University Of Freiburg· Source

• Recruiting

  Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management

  NCT05362760· Phase 4· Prof. Wolfgang Janni· Source

• Active, not recruiting

  Daratumumab for first line treatment of transplant-ineligible myeloma patients followed by daratumumab re-treatment at first relapse (GMMG-DADA)

  2024-517761-17-00· Phase 2· University Of Cologne· Source

• Active, not recruiting

  Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)

  NCT03617731· Phase 3· University of Heidelberg Medical Center· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Triple-negative breast cancer3 recruiting
• Metastatic breast cancer2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Lung cancer1 recruiting
• Multiple myeloma1 recruiting

Closed trials

• Active, not recruiting

  Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma

  NCT06216158· Phase 3· University of Heidelberg Medical Center· Source

• Active, not recruiting

  Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone

  NCT03104842· Phase 2· Universitätsklinikum Hamburg-Eppendorf· Source

• Completed

  autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European MCL Network trial

  2024-511235-10-00· Phase 3· Klinikum der Universitaet Muenchen AöR· Source

• Completed

  HD21

  NCT02661503· Phase 3· University Of Cologne· Source